MET and non-small cell lung carcinoma: For another type of NSCLC with activation of the c-MET pathway, the efficacy of MET inhibitors (crizotinib and capmatinib, INC280) is being assessed either as monotherapy (NCT02414139) or in combination with epidermal growth factor (EGF) tyrosine kinase inhibitor erlotinib (NCT01911507).